Encompass Health Corporation EHC R3KPHARMA
Company Overview
Encompass Health Corporation operates inpatient rehabilitation hospitals in the United States and Puerto Rico. The company offers specialized rehabilitative treatment, using technology and therapy, on an inpatient basis for patients recovering from a major injury or illness and seeking to regain functional ability, independence, and quality of life; medical, nursing, therapy, and ancillary services; and rehabilitative care to patients who are recovering from conditions, such as stroke and other neurological disorders, cardiac and pulmonary conditions, brain and spinal cord injuries, complex orthopedic conditions, and amputations. It offers services through the Medicare program to the federal government, managed care plans and private insurers, state governments, and other patients. The company was formerly known as HealthSouth Corporation and changed its name to Encompass Health Corporation in January 2018. Encompass Health Corporation was incorporated in 1984 and is based in Birmingham, Alabama.
Why Investors Should Care
Generates a return on equity of 25.0%, reflecting efficient use of shareholder capital.
Trades at a P/E of 20.1, below the sector median of 24.8.
Operating margin of 18.1% supports profitability.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $5.94B (+10.5% YoY); net profit $566.20M.
- Trailing 12 Months Year-on-year growth — revenue +9.6%, earnings +10.8%.
- 5-Year Trend Long-term compounding — revenue CAGR 5.6%, profit CAGR 4.9%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 5.57% |
| 1 Year: | 9.60% |
Compounded Profit Growth
| 5 Years: | 4.87% |
| 1 Year: | 10.80% |
Stock Price Performance
| 1 Year: | +1.85% |
| 6 Months: | +11.34% |
| 3 Months: | +19.37% |
| 1 Month: | -3.80% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)53.11 · Neutral
P/E of 20.11 is below the sector median of 24.83 — relatively cheaper than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 25.0%.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | EHC Encompass Health Corporation R3KPHARMA | 120.47 | 20.11 | $11.88B | 0.70% | 8.63% | 24.97% | 5.57% | 4.87% |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | 957.10M | 966.40M | 981.60M | 1.01B | 1.05B | 1.07B | 1.07B | 1.10B | 1.12B | 1.14B | 1.16B | 1.18B | 1.18B | 1.07B | 1.17B | 1.21B | 959.90M | 1.00B | 1.01B | 1.04B | 1.06B | 1.06B | 1.09B | 1.14B | 1.16B | 1.19B | 1.21B | 1.32B | 1.30B | 1.35B | 1.46B | 1.46B | 1.48B | 1.59B | 1.60B |
| Operating Income | 135.50M | 144.20M | 150.20M | 148.20M | 145.50M | 147.10M | 141.30M | 145.20M | 144.70M | 150.00M | 157.30M | 154.50M | 93.40M | 167.10M | 152.60M | 151.20M | 141.20M | 159.30M | 85.20M | 151.10M | 168.30M | 143.00M | 146.80M | 141.40M | 128.40M | 131.50M | 128.60M | 127.50M | 151.90M | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | 47.00M | 58.00M | 62.60M | 61.70M | 65.30M | 66.80M | 63.00M | 65.90M | 75.40M | 83.80M | 91.80M | 88.60M | 28.10M | 102.30M | 91.20M | 97.60M | 67.60M | 87.00M | 33.50M | 77.70M | 86.00M | 107.30M | 113.30M | 100.00M | 91.60M | 87.50M | 48.70M | 45.40M | 89.40M | 87.70M | 91.40M | 85.30M | 112.50M | 114.10M | 108.20M | 151.50M | 142.10M | 126.50M | 194.50M | 153.90M |
| Diluted EPS | 0.49 | 0.61 | 0.65 | 0.64 | 0.68 | 0.70 | 0.70 | 0.67 | 0.76 | 0.84 | 0.92 | 0.89 | 0.28 | 1.03 | 0.92 | 0.98 | 0.68 | 0.87 | 0.34 | 0.78 | 0.86 | 1.07 | 1.13 | 1.00 | 0.91 | 0.87 | 0.49 | 0.45 | 0.89 | 0.87 | 0.90 | 0.84 | 1.10 | 1.12 | 1.06 | 1.48 | 1.39 | 1.24 | 1.93 | 1.54 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | 3.64B | 3.91B | 4.28B | 4.61B | 3.57B | 4.01B | 4.35B | 4.80B | 5.37B | 5.94B |
| Operating Income | - | - | - | - | - | - | - | 485.70M | 588.10M | 578.30M | 555.20M | 612.10M | 563.90M | 559.60M | 539.50M | - | - | - |
| Net Income | 252.40M | 94.80M | 899.00M | 208.70M | 185.00M | 323.60M | 222.00M | 183.10M | 247.60M | 271.10M | 292.30M | 358.70M | 284.20M | 412.20M | 271.00M | 352.00M | 455.70M | 566.20M |
| Diluted EPS | 2.62 | 0.77 | 8.28 | 1.96 | 1.67 | 2.58 | 2.29 | 1.91 | 2.59 | 2.84 | 2.93 | 3.61 | 2.85 | 4.11 | 2.70 | 3.47 | 4.46 | 5.54 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 1.68B | 2.37B | 2.27B | 2.42B | 2.53B | 3.39B | 4.61B | 4.68B | 4.86B | 5.17B | 6.08B | 6.45B | - | 5.64B | 6.10B | 6.53B | 7.09B |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 717.20M | 841.80M | 886.90M | 905.90M |
| Cash & Equivalents | - | 31.70M | 80.70M | 48.30M | 30.10M | 132.80M | 64.50M | 66.70M | 61.60M | 40.50M | 54.40M | 69.20M | 60.00M | 185.60M | - | 21.80M | 69.10M | 85.40M | 72.20M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 536.80M | 611.60M | 598.80M | 619.20M |
| Total Liabilities | - | - | 2.19B | 1.99B | 1.68B | 1.67B | 1.96B | 2.59B | 3.71B | 3.61B | 3.25B | 3.36B | 4.15B | 4.44B | - | 3.77B | 3.81B | 3.69B | 3.81B |
| Current Liabilities | - | - | 391.20M | 359.30M | 313.20M | 300.90M | 311.60M | 364.30M | 426.40M | 475.60M | 517.50M | 672.50M | 721.00M | 717.30M | - | 575.90M | 656.40M | 841.00M | 836.40M |
| Long Term Debt | - | - | 1.64B | 1.50B | 1.24B | - | - | - | - | - | - | - | - | - | - | 2.74B | 2.69B | 2.36B | 2.45B |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.99B | 2.93B | 2.71B | 2.71B |
| Total Equity | -1.46B | -1.09B | -897.60M | -85.20M | 117.00M | 291.00M | 344.60M | 473.20M | 611.40M | 735.90M | 1.15B | 1.28B | 1.35B | 1.59B | - | 1.31B | 1.65B | 2.07B | 2.44B |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 114.78M | 115.42M | 116.04M | 116.04M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 227.20M | 406.10M | 331.00M | 342.70M | 411.50M | 470.30M | 444.90M | 502.00M | 640.20M | 658.30M | 762.40M | 635.30M | 704.70M | 715.80M | 705.80M | - | - | - |
| Investing Cash Flow | -40.00M | -133.00M | -125.90M | -24.60M | -178.80M | -226.20M | -876.90M | -1.13B | -229.90M | -283.00M | -424.50M | -657.40M | -407.50M | -666.30M | -627.00M | -602.80M | -653.30M | -764.60M |
| Financing Cash Flow | -176.00M | -224.30M | -237.50M | -336.30M | -130.00M | -312.40M | 434.20M | 622.70M | -416.40M | -359.90M | -321.20M | 48.20M | -145.90M | -240.10M | -145.70M | -197.20M | -330.60M | -431.20M |
| Capital Expenditure | -55.70M | -63.30M | -62.80M | -100.30M | -140.80M | -195.20M | -170.90M | -128.40M | -177.70M | -225.80M | -254.50M | -372.40M | -392.80M | -524.60M | -564.80M | - | - | - |
| Free Cash Flow | 171.50M | 342.80M | 268.20M | 242.40M | 270.70M | 275.10M | 274.00M | 373.60M | 462.50M | 432.50M | 507.90M | 262.90M | 311.90M | 191.20M | 141.00M | - | - | - |
| Share Buybacks | - | - | - | 0 | 0 | 234.10M | 43.10M | 45.30M | 65.60M | 38.10M | 0 | 45.90M | 6.10M | 0 | 0 | 0 | 31.10M | 158.00M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - | - | 16.1% | 14.8% | 13.0% | 13.3% | 15.8% | 13.9% | 12.4% | - | - | - |
| Net Margin % | - | - | - | - | - | - | - | - | 6.8% | 6.9% | 6.8% | 7.8% | 8.0% | 10.3% | 6.2% | 7.3% | 8.5% | 9.5% |
| ROE % | -23.2% | -10.6% | -1,055.2% | 178.4% | 63.6% | 93.9% | 46.9% | 29.9% | 33.6% | 23.5% | 22.9% | 26.5% | 17.9% | - | 20.7% | 21.4% | 22.0% | 23.2% |
| ROCE % | - | - | - | - | - | - | - | 11.6% | 14.0% | 13.3% | 12.3% | 11.4% | 9.8% | - | 10.7% | - | - | - |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 10.63% | 10.48M | $1.28B |
| 2 | Price (T.Rowe) Associates Inc | 5.12% | 5.06M | $615.54M |
| 3 | Vanguard Portfolio Management LLC | 4.99% | 4.92M | $599.58M |
| 4 | Vanguard Capital Management LLC | 4.54% | 4.48M | $544.94M |
| 5 | Wellington Management Group, LLP | 3.32% | 3.28M | $399.19M |
| 6 | State Street Corporation | 3.23% | 3.19M | $387.87M |
| 7 | Citadel Advisors Llc | 2.60% | 2.56M | $312.06M |
| 8 | Alliancebernstein L.P. | 2.51% | 2.47M | $300.94M |
| 9 | Fuller & Thaler Asset Management Inc. | 2.49% | 2.46M | $299.58M |
| 10 | Two Sigma Investments, LP | 2.30% | 2.27M | $276.09M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for EHC
Encompass Health (EHC) Stock Gets Fair Value Bump After Analysts Lift Targets - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMinAFBVV95cUxOVUk4NGtyTnpQeVplME9KMkRFdndaSXVJdEU0ZngyNTM1b2JRM0VDYlowMmd4NUdrbzQ3NTUzd3pjUlVKVXR0ODBkbmR0OTIwSmJOTWJlWnhraWk5WkFuMktXVlROYjFUQ3hUTWNmZDV2VkZaaC0tbGszbGlQMjZmbEs5YmF2UExUcTFaZj…
Encompass Health Corporation (EHC) Stock Analysis: Exploring A 21.66% Potential Upside - directorstalkinterviews.com
<a href="https://news.google.com/rss/articles/CBMizgFBVV95cUxQMXByaFM1Y0lxZDM5Vkp1SUltbzB3ZjJsTGluSXk3QXI0cE9IUHdkOW40S1dadmZxZVl1elBlRFQzMTVJZVRoMUN4YkNjV0ZUR0FVOGZsWWpxRFh0Zl9fdHJvUFhMMEs0bHBYbHBqZXo2OFk4UDJFS05WRkxqd1p0N0FBa2dIUnJzTmtSc2…
Encompass Health (EHC) Stock Still Looks Like A Bargain Despite Its 100% Run - simplywall.st
<a href="https://news.google.com/rss/articles/CBMizwFBVV95cUxQTG9jbkVvcDFFa0FlQkg2dFRqOGpZeWNaZy05bVdBUVIxbl9Hdk43bjRzTklCejNwcUtGM0U4NFZmSldsc2V0amc5Ymc4YkVNREJ6SVdhbDBmX29FQU9jWGFtLW80QlQzOGJTeGZDVlRnM2ZMRF8tNmszclBhVWs1ZWRyQi1PZ1Q3VVJRSj…
Encompass Health (NYSE: EHC) officer to sell 4,858 shares - Stock Titan
<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxONHRPeUlwSDlfa1Z5ZWd0cGp2SHBNUXFiZDRtcmV6QVhpaTVSUDNtbzdaQjIxU1ZrRXlrc0JNSUFVQjJtN0U3UGJ0MU9WTDBEWW5QTGQ4SEptMVJLR1lpZzhYNlFwUGhJV01sWEEwYTZlUWI4OFhFWDVDV1g1RjJQUkhvN3NvbjktMHNFX1…
Encompass Health (EHC) Shares Skyrocket, What You Need To Know - StockStory
<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxPcDJQMFpac0JPWlNVZDFMSWE0ZjN0N1VTM3I2d0hJSTdKdjJrWG90QzRzTE1ZUThBRklyOGRmdVZxYTMySlg3RXhEZUg1UDNXN0dQN2xSeE1Xb3p6QjdMWjgwSjNwMU1wUHloNTJCNF9wTGVlLUlGZXBZOHlLSGxsdXpTUjlCRUstODVWUm…
Why Is Encompass Health (EHC) Down 1.8% Since Last Earnings Report? - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxNYTEydHhIdl9tM2FXUTltOUxNMldtZzZicDZ6b1pEZzlGN3Y0ZEU4OUZwZU1NU093QUpxWG5fV2hrZDN4aW9kZkVWMkNSQzVaOG9KREZfMkdZOUZlSjV1Zm5sdnV1U3lzUG9TSDRwWHM1QXBuNGRuRnYxR2VwZWpfT0lidDROVFYyWDJOTH…
EHC — Frequently Asked Questions
What is the current share price of Encompass Health Corporation (EHC)?
As of 2026-09-19 21:16 PDT, Encompass Health Corporation (EHC) trades at $120.47 on NYSE. Its 52-week range is $93.47 to $126.46.
What is the market capitalisation of EHC?
Encompass Health Corporation (EHC) has a market capitalisation of $11.88B on NYSE.
What is the P/E ratio of EHC?
EHC trades at a trailing price-to-earnings (P/E) ratio of 20.11. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 4.62.
Does EHC pay a dividend?
Encompass Health Corporation (EHC) currently offers a dividend yield of 0.70%.
What is the return on equity (ROE) of EHC?
EHC has a return on equity (ROE) of 24.97%. Its return on capital employed (ROCE) is 8.63%.
Is EHC a good stock to buy?
This page provides a data-driven analysis of Encompass Health Corporation (EHC), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.